- Home
- AREC vs LCTX Comparison
AREC vs LCTX Comparison
Compare AREC & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AREC | LCTX |
|---|---|---|
| Founded | 2013 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.4M | 255.4M |
| IPO Year | 2013 | 1996 |
Fundamental Metrics
Financial Performance| Metric | AREC | LCTX |
|---|---|---|
| Price | $1.78 | $0.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $6.50 | $6.25 |
| AVG Volume (30 Days) | ★ 1.4M | 1.2M |
| Earning Date | 06-01-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 223.53 | N/A |
| EPS | ★ 0.63 | N/A |
| Revenue | N/A | ★ $14,556,000.00 |
| Revenue This Year | N/A | $109.40 |
| Revenue Next Year | $38,462.50 | N/A |
| P/E Ratio | $2.90 | ★ N/A |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $1.48 | $0.91 |
| 52 Week High | $7.11 | $2.09 |
Technical Indicators
Market Signals| Indicator | AREC | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 30.24 | 37.83 |
| Support Level | $1.48 | N/A |
| Resistance Level | $2.55 | $1.18 |
| Average True Range (ATR) | 0.09 | 0.06 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 1.89 | 12.72 |
Price Performance
Historical ComparisonAbout AREC American Resources Corporation
American Resources Corp is engaged in the aggregation, recovery, recycling, and sale of recovered metal and steel materials. The company operates through two segments: Corporate and Electrified Materials. The Electrified Materials segment focuses on processing and recycling recovered metal and steel products.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.